Treatment strategies for high-risk locally advanced prostate cancer

Nature Reviews Urology

Volumn 7, Issue 1, 2010, Pages 31-38

  Rosenthal, Seth A ^a   Sandler, Howard M ^b  

^a Radiological Associates of Sacramento Medical Group Inc   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CELECOXIB; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GONADORELIN; GOSERELIN; LEUPRORELIN; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTIANDROGEN THERAPY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DOSIMETRY; GLEASON SCORE; HUMAN; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 75949124984     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.237     Document Type: Review

References (89)

1. Jemal, A. et al. Cancer Statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Albertsen, P. C., Fryback, D. G., Storer, B. E., Kolon, T. F. & Fine, J. Long-term survival among men with conservatively treated prostate cancer. JAMA 274, 626-631 (1995).
3. Albertsen, P. C. A challenge to contemporary management of prostate cancer. Nat. Clin. Pract. Urol. 6, 12-13 (2009).
4. Ryan, C. J., Elkin, E. P., Cowan, J. & Carroll, P. R. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer 110, 81-86 (2007).
5. American Joint Committee on Cancer. AJCC Staging Manual, 6th edn (Springer, New York, 2002).
6. Gleason, D. F. & Mellinger, G. T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 111, 58-64 (1974).
7. Zagars, G. K., Ayala, A. G., von Eschenbach, A. C. & Pollack, A. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long term-follow-up study of 648 patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 31, 237-245 (1995).
8. Rioux-Leclercq, N. C., Chan, D. Y. & Epstein, J. I. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8-10 adenocarcinoma. Urology 60, 666-669 (2002).
9. Bastian, P. J. et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason Sum of 8 to 10. Cancer 107, 1265-1272 (2006).
10. Zagars, G. K., Pollock, A. & Eschenbach, A. C. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79, 1370-1380 (1997).
11. Mitchell, R. E. et al. Preoperative serum prostate specific antigen remains a significant prognostic variable in predicting biochemical failure after radical prostatectomy. J. Urol. 175, 1663-1667 (2006).
12. Inman, B. A. et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level of > or = 50 ng/ml. Cancer 113, 1544-1551 (2008).
13. Pisansky, T. M., Kahn, M. J. & Bostwick, D. G. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 79, 2154-2161 (1997).
14. Soloway, M. & Roach, M. Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era. Cancer 104, 2310-2322 (2005).
15. Partin, A. W. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277, 1445-1451 (1997).
16. Kattan, M. W., Eastham, J. A., Stapleton, A. M., wheeler, T. M. & Scardino, P. T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst. 90, 766-771 (1998).
17. Kattan, M. W. et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. . Clin. Oncol. 18, 3352-3359 (2000).
18. D'Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969-974 (1998).
19. Greene, K. L. et al. who is the average patient presenting with prostate cancer? Urology 66, 76-82 (2005).
20. D'Amico, A. V., Chen, M. H., Roehl, K. A. & Catalona, W. J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 351, 125-135 (2004).
21. D'Amico, A. V. , Renshaw, A. A., Sussman, B. & Chen, M. H. Preoperative PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294, 440-447 (2005).
22. Hanks, G. E., Hanlon, A. L., Lee, W. R., Slivjak, A. & Schultheiss, T. E. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int. J. Radiat. Oncol. Biol. Phys. 34, 549-553 (1996).
23. Roberts, S. G., Blute, M. L., Bergstralh, E. J., Slezak, J. M. & Zincke, H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin. Proc. 76, 576-581 (2001).
24. Grossfeld, G. D. et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology 59, 560-565 (2002).
25. Dong, F. et al. Prostate cancer volume at biopsy predicts clinically significant upgrading. J. Urol. 179, 896-900 (2008).
26. whittemore, D. E. et al. Significance of tertiary Gleason pattern 5 in Gleason Score 7 radical prostatectomy specimens. J. Urol. 179, 516-522 (2008).
27. Nanda, A., Chen, M. H., Renshaw, A. A. & D'Amico, A. V. Gleason pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int. J. Radiat. Oncol. Biol. Phys. 74, 1419-1423 (2009).
28. Roach, M., waldman, F. & Pollack, A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 115, 3112-3120 (2009).
29. Pilepich, M. V. et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J. Clin. Oncol. 15, 1013-1021 (1997).
30. Lawton, C. A. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 49, 937-946 (2001).
31. Pilepich, M. V. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate adenocarcinoma-long-term results of phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61, 1285-1290 (2005).
32. Pilepich, M. V. et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45, 616-623 (1995).
33. Pilepich, M. V. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 50, 1243-1252 (2001).
34. Roach, M. et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26, 585-591 (2008).
35. D'Amico, A. V. et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 , 821-827 (2004).
36. Denham, J. W. et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results form the Trans-Tasman Radiation Oncology group 96.01 randomised controlled trial. Lancet Oncol. 6, 841-850 (2005).
37. Bolla, M. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337, 295-300 (1997).
38. Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103-106 (2002).
39. Bolla, M., Descotes, J. L., Artignan, X. & Fourneret, P. Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer. BJU Int. 100, 44-47 (2007).
40. Hanks, G. E. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Trial 92-02. J. Clin. Oncol. 21, 3972-3978 (2003).
41. Horwitz, E. M. et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26, 2497-2504 (2008).
42. Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516-2527 (2009).
43. widmark, A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373, 301-308 (2009).
44. Rosenthal, S. A. Prostate cancer: local control and radiotherapy matter in prostate cancer. Nat. Rev. Urol. 6, 250-251 (2009).
45. Nanda, A. et al. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. doi:10.1016/j.ijrobp.2009.03.034.
46. Crook, J. et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 60, 15-23 (2004).
47. Roach, M. et al. Predicting the risk lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 28, 33-37 (1994).
48. Roach, M. et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J. Clin. Oncol. 21, 1904-1911 (2004).
49. Lawton, C. A. et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int. J. Radiat. Oncol. Biol. Phys. 69, 646-655 (2007).
50. Pommier, P. et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary Results of GETUG-01. J. Clin. Oncol. 25, 5366-5373 (2007).
51. Nguyen, P. L. & D'Amico, A. V. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J. Clin. Oncol. 26, 2055-2056 (2008).
52. Shahinian, V. B., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154-164 (2005).
53. Feigenberg, S. J. et al. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 62, 397-405 (2005).
54. D'Amico, A. V. et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction. J. Clin. Oncol. 25, 2420-2425 (2007).
55. Saigal, C. S. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110, 1493-1500 (2007).
56. Tsai, H. K., D'Amico, A. V. , Sadetsky, N., Chen, M. H. & Carroll, P. R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl Cancer Inst. 99, 1516-1524 (2007).
57. Lawton, C. A., Bae, K., Pilepich, M., Hanks, G. & Shipley, w. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int. J. Radiat. Oncol. Biol. Phys. 70, 437-441 (2008).
58. Israeli, R. S., Ryan, C. W. & Jung, L. L. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J. Urol. 179, 414-423 (2008).
59. Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009).
60. Rosenthal, S. A. et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int. J. Radiat. Oncol. Biol. Phys. 73, 672-678 (2009).
61. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004).
62. James, N. D. et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int. 103, 464-469 (2008).
63. Oh, W. K. An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer. J. Urol. 172, S34-S37 (2004).
64. Eastham, J. A., Kelly, w. K., Grossfeld, G. D. & Small, E. J. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62, 55-62 (2003).
65. Flaig, T. W. et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J. Clin. Oncol. 26, 1532-1536 (2008).
66. Pollack, A. et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53, 1097-1105 (2002).
67. Dearnaley, D. P. et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br. J. Cancer 92, 488-498 (2005).
68. Zeitman, A. L. et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294, 1233-1239 (2005).
69. Dearnaley, D. P. et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8, 475-487 (2007).
70. Al-Mamgani, A. et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 72, 980-988 (2008).
71. Kuban, D. A. et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 67-74 (2008).
72. Martinez, A. A. et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 53, 316-327 (2002).
73. Vicini, F. A., Vargas, C., Edmunson, G., Kestin, L. & Martinez, A. The role of high-dose rate brachytherapy in locally advanced prostate cancer. Semin. Radiat. Oncol. 13, 98-108 (2003).
74. Demanes, D. J., Rodriguez, R. R., Schour, L., Brandt, D. & Altieri, G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int. J. Radiat. Oncol. Biol. Phys. 61, 1306-1316 (2005).
75. Lee, W. R. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology 60, 39-44 (2002).
76. Stock, R. G., Ho, A., Cesaretti, J. A. & Stone, N. N. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int. J. Radiat. Oncol. Biol. Phys. 66, 389-394 (2006).
77. Stock, R. G., Cesaretti, J. A., Hall, S. J. & Stone, N. N. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int. 104, 1631-1636 (2009).
78. Stone, N. N. et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 73, 341-346 (2009).
79. Mohler, J. L. Updating the prostate cancer guidelines. J. Natl Compr. Canc. Netw. 5, 647-648 (2007).
80. Thompson, I. M. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 2329-2335 (2006).
81. Bolla, M. et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 366, 572-576 (2005).
82. weigel, T. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27, 2924-2930 (2009).
83. Thompson, I. M. et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181, 956-962 (2009).
84. Aragon-Ching, J. B. & Dahut, W. L. The role of angiogenesis inhibitors in prostate cancer. Cancer J. 14, 20-25 (2008).
85. Aragon-Ching, J. B. & Dahut, W. L. VEGF inhibitors and prostate cancer therapy. Curr. Mol. Pharmacol. 2, 161-168 (2009).
86. Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571 (2008).
87. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790 (2009).
88. Nilsson, S. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 8, 587-594 (2007).
89. Tu, S. M. & Lin, S. H. Current trials using bone-targeting agents in prostate cancer. Cancer J. 14, 35-39 (2008).